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1  | INTRODUC TION
Electroconvulsive therapy (ECT) is considered to be the most ef‐
fective therapy for severe major depressive disorder (MDD) with 
reported effectiveness rates between 80% and 90% (UK ECT 
Review Group, 2003). Indication of ECT as the first‐line treatment 
is a need for rapid, definitive response because of the severity of 
the psychotic or suicidal symptoms as well as a favorable prior re‐
sponse to ECT. Treatment resistance is a secondary indication for 
ECT (American Psychiatric Association, 2001). ECT is well toler‐
ated; for example, it does not cause long‐term cognitive impair‐
ment (Haghighi et al., 2016; Haghighi, Bajoghli, et al., 2013).
Molecules in several brain areas are affected by ECT includ‐
ing neurotransmitters, neuropeptides, and neurotrophic factors 
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Abstract
Objectives: Brain‐derived neurotrophic factor (BDNF) has been associated with de‐
pression and its treatment response. The aim of the present study was to explore the 
effect of electroconvulsive therapy (ECT) on serum and plasma BDNF levels and 
change of Montgomery–Asberg Depression Rating Scale (MADRS) and their associa‐
tions in patients with major depressive disorder (MDD).
Methods: The study included thirty patients suffering from MDD. Their serum and 
plasma BDNF levels were examined before ECT (baseline) and after the first, fifth, 
and last ECT session. The severity of the depression and the response to ECT were 
measured with MADRS.
Results: Electroconvulsive therapy caused no significant changes in serum BDNF lev‐
els. Plasma BDNF levels decreased during the fifth ECT session between the baseline 
and the 2‐hr samples (p = 0.019). No associations were found between serum or 
plasma BDNF levels and remission. The correlations between plasma and serum 
BDNF levels in each measurement varied between 0.187 and 0.636.
Conclusions: Neither serum nor plasma BDNF levels were systematically associated 
with the clinical remission. However, the plasma BDNF levels somewhat varied 
 during the ECT series. Therefore, the predictive value of BDNF for effects of ECT 
appears to be at least modest.
K E Y W O R D S
brain‐derived neurotrophic factor, electroconvulsive therapy, major depressive disorder, 
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(Wahlund & von Rosen, 2003). It has been demonstrated that elec‐
troconvulsive stimulation (ECS), an animal model of ECT, induced 
neurogenesis in rat hippocampus suggesting that the effect of ECT 
may be related to the stimulation of cellular and synaptic plasticity 
in the hippocampal formation (Madsen et al., 2000).
Brain‐derived neurotrophic factor (BDNF) is a member of the 
neurotrophin family of trophic factors and is abundantly expressed 
in the central nervous system, especially in the hippocampus and 
cerebral cortex (Altar, 1999; Leibrock et al., 1989; Lewin & Barde, 
1996). BDNF is involved in stimulating the development and differ‐
entiation of new neurons, neuron survival, and promoting long‐term 
potentiation (Noble, Billington, Kotz, & Wang, 2011). Molendijk et al. 
(2014) concluded in a meta‐analysis that serum BDNF levels were 
reduced in patients suffering from MDD and that the BDNF levels 
were elevated following a course of antidepressant drug treatment 
(Molendijk et al., 2014).
Increased BDNF expression has been reported to mediate the 
antidepressant effects of a range of antidepressants as well as 
ECS in some animal studies (Castrén & Rantamäki, 2010). Levels of 
BDNF have been reported to rise in various parts of rodent brain 
after	ECS	(Angelucci,	Aloe,	Jimenez‐Vasquez,	&	Mathe,	2002),	(Altar,	
Whitehead, Chen, Wörtwein, & Madsen, 2003). However, there is 
also an opposite finding observing no change in BDNF concentration 
in	rodent	brain	areas	after	ECS	(Angelucci,	Aloe,	Jimenez‐Vasquez,	&	
Mathe, 2003). Secretion of the precursor of BDNF, proBDNF, was 
recently found to be increased in rat hippocampus after a single ad‐
ministration of ECS. After repeated ECS, accumulation of proBDNF 
resulted in an increase in BDNF (Segawa, Morinobu, Matsumoto, 
Fuchikami, & Yamawaki, 2013). However, the importance of the ro‐
dent forced swim stressor test (FST) used as a depression model in 
studies concerning the pathogenesis and treatment of mood disor‐
ders	has	been	questioned.	In	a	recent	review	article,	the	conclusion	
was that the rodent’s behavioral response to FST reflects stress cop‐
ing and adaptation mechanisms rather than depression (De Kloet & 
Molendijk, 2016).
In human studies, the findings on the changes in BDNF and the 
response to ECT are controversial (Pinna et al., 2016). Some studies 
have suggested that ECT increases serum or plasma BDNF levels at 
different time points after ECT (Bilgen et al., 2014; Bocchio‐Chiavetto 
et al., 2006; Bumb et al., 2014; Haghighi, Salehi, et al., 2013; Hu et 
al., 2010; Marano et al., 2007; Okamoto et al., 2008; Piccinni et al., 
2009; Salehi et al., 2016). However, there are several studies which 
have reported no influence of ECT on serum or plasma BDNF levels 
during or after ECT series (Fernandes et al., 2009; Gedge et al., 2012; 
Grønli, Stensland, Wynn, & Olstad, 2009; Kleimann et al., 2014; Lin 
et	 al.,	 2013;	Rapinesi	 et	 al.,	 2015).	 These	 studies	 examined	 either	
serum or plasma levels of BDNF mainly before and after ECT series. 
It is not yet understood whether these findings reflect the processes 
in central nervous system during ECT.
The aim of the present study was to examine the predictive 
effect of serum and plasma BDNF levels on remission in patients 
with MDD at three stages during the ECT series. The three stages 
were designed to examine the immediate impact of ECT on serum 
and plasma levels of BDNF at specific time points during ECT series. 
Also, the aim was to find out whether the findings between serum 
and plasma BDNF levels were consistent with each other.
2  | PATIENTS AND METHODS
The study group consisted of 36 eligible patients (17 females and 
19 male) consecutively admitted for ECT to the Department of 
Psychiatry, Tampere University Hospital. Six patients withdrew 
from the study, so that the final study population consisted of 30 
patients (12 females and 18 male). The patients were recruited be‐
tween November 2011 and May 2013. On admission, the struc‐
tured	clinical	interview	for	DSM‐IV	disorders	interview	(SCID)	(First,	
Spitzer, Gibbon, & Williams, 1996) was conducted with each patient 
to	confirm	the	diagnosis.	All	patients	fulfilled	the	DSM‐IV	diagnostic	
criteria for major depressive disorder (MDD) (American Psychiatric 
Association, 1994), and 14 of them had psychotic symptoms. Nine 
patients had suffered their first episode of MDD, and 21 patients 
were suffering from recurrent MDD.
Patients with progressive organic brain disorder, other major 
psychiatric disorder than MDD, inflammatory or autoimmune dis‐
ease, epilepsy, and alcohol or other substance abuse were excluded 
from the study. Patients who had received ECT within 3 months 
prior to entry into the study were also excluded.
The	 mean	 age	 of	 the	 patients	 was	 57.1	years	 (SD 17.7, range 
25–85	years).	The	patients	were	given	constant	psychotropic	drug	
treatment throughout the entire ECT period (Table 1). Twenty‐eight 
patients in the study were taking a combination of at least two 
psychotropic medications, and only two were on monotherapy. 
Benzodiazepines were discontinued 10 hr before ECT to avoid ef‐
fects on seizure threshold.
The	severity	of	the	depression	was	quantified	by	the	Montgomery–
Asberg Depression Rating Scale (MADRS) (Montgomery & Åsberg, 
1979) before the first and after the fifth and last ECT.
Before the first ECT treatment, a medical history, a physical ex‐
amination with routine blood examinations, and end electrocardio‐
gram	 (ECG)	were	 requested.	ECT	was	administered	 three	 times	a	
week with a brief pulse constant current device MECTA SPECTRUM 
5000Q	(MECTA	Corp.,	Lake	Oswego,	OR,	USA).	Seizure	threshold	
was	titrated	at	treatment	1,	and	subsequent	treatments	were	ad‐
ministered	at	1.5	times	the	seizure	threshold	for	bilateral	(BL)	ECT.	
Seizures	over	25	s	in	duration	in	EEG	were	deemed	adequate.
Anesthesia was induced with methohexital and muscle re‐
laxation with succinylcholine. The initial dose was 1 mg/kg of 
methohexital	and	0.5	mg/kg	of	succinylcholine.	The	patients	were	
ventilated with 100% oxygen until resumption of spontaneous res‐
piration. Physiological monitoring during the treatment included 
pulse oximetry, blood pressure, ECG, one‐channel electroen‐
cephalogram (EEG), and electromyography (EMG). All the patients 
were treated with standard bilateral (bifrontotemporal) ECT. The 
number	of	treatments	ranged	between	5	and	17,	10.4	±	3.6	(mean,	
±SD). ECT treatment was discontinued on the basis of clinical 
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judgment	 if	 the	patient	was	either	 in	 remission	 (MADRS	≤	10)	or	
no further improvement was recorded during last two ECT ses‐
sions. In five patients, the fifth ECT was the last (not included in 
last ECT session data).
Blood was drawn before ECT (baseline) and 2 hr and 4 hr after 
ECT at the first, fifth, and last session, and EDTA plasma/serum (P/S) 
was	separated	and	stored	at	−80	C	until	analyzed.	The	concentration	
of BDNF in plasma/serum samples was determined using enzyme‐
linked immunosorbent assay (DuoSet ELISA; R&D Systems Europe, 
Ltd, Abingdon, UK).
All patients gave written informed consent. This study design 
was reviewed and approved by the Tampere University Hospital 
Ethics Committee.
2.1 | Statistical methods
Differences in serum BDNF or plasma BDNF levels between dif‐
ferent measurements (baseline; after 2 hr and after 4 hr at the first, 
fifth, and last ECT treatment sessions; and between baseline levels 
of first, fifth, and last treatment sessions) were calculated with re‐
peated	samples	ANOVA.	Pearson	correlations	were	used	for	com‐
parisons between simultaneous S‐BDNF and P‐BDNF levels in each 
measurement. Due to nonnormal distributions, logarithmic transfor‐
mations were used for P‐BDNF measurements in all analyses. The 
level of statistical level was set at p	<	0.05.	All	significant	differences	
are also reported as effect sizes (Cohen’s d). Power analysis showed 
that, with the current sample, a difference of 1.89 ng/ml in serum 
BDNF levels between paired samples was detectable with a power 
of 0.8. Calculations were performed with R (version 3.2.0), SPSS for 
Windows (version 22.0; IBM Inc.), and PS Power and Sample size 
calculator software (Dupont & Plummer, 1990).
3  | RESULTS
At	baseline,	the	mean	MADRS	score	was	31.6	±	7.2	(mean	±	SD), and 
after	ECT	series,	the	mean	score	was	11.3	±	7.5.	At	the	end	of	the	
study,	20	of	30	patients	were	in	remission	(MADRS	≤	10).
Electroconvulsive therapy caused no significant changes in 
serum	 BDNF	 levels	 (mean	 levels	 25.1–27.3	ng/ml)	 between	 and	
during the first, fifth, and last ECT sessions (Figure 1). There was no 
correlation between baseline (before the first ECT) serum BDNF and 
severity of depression measured by MADRS. Baseline serum BDNF 
did not predict the later remission rate after the treatment period.
Plasma BDNF concentrations of the present patients were 
around one‐fourth compared to serum levels (variation 6.1–11.4  
ng/ml). More variation in plasma BDNF was seen than in serum lev‐
els. The correlations between plasma and serum BDNF levels in each 
measurement varied between 0.187 and 0.636 (Pearson correlation 
coefficient).
All patients 
(n  = 30)
Female patients 
(n  = 12)
Male patients 
(n = 18)
Age,	mean,	±SD 
range
57.1,	±17.7 
25–85
71.1	±	12.2 
45–85
45.2	±	17.0 
25–79
Total number of ECTs, mean, 
±SD 
range
10.4,	±3.6 
5–17
10.8	±	4.3 
5–17
8.2	±	3.6 
5–13
Psychotic symptoms 14 7 7
First episode of MDD 9 4 5
Recurrent MDD 21 13 8
Antidepressants
SSRI 9 3 6
SNRI 12 5 7
Mirtazapine 12 6 6
Bupropion 4 1 3
Antipsychotics
Second‐generation 
antipsychotics
28 11 17
Conventional neurolepts 1 0 1
Anxiolytics
Benzodiazepines 21 8 13
Pregabalin 2 2 0
Buspirone 1 0 1
Note. SNRI: serotonin and norepinephrine reuptake inhibitor; SSRI: Selective serotonin reuptake 
inhibitor.
TA B L E  1   Psychotropic medications of 
patients with MDD during the ECT series
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Plasma BDNF levels fell during the fifth ECT session between 
baseline and the 2‐hr samples (p = 0.038, d	=	0.45).	No	 significant	
changes were found in plasma BDNF levels during the first ECT ses‐
sion, but there was a decreasing trend between baseline and 2‐hr 
plasma BDNF levels during the last ECT session (p = 0.079, d = 0.42). 
No associations were found between any plasma BDNF levels and 
their changes and remission.
4  | DISCUSSION
In the present study, serum BDNF levels were not influenced by ECT. 
In plasma, the BDNF levels decreased during the fifth ECT session 
between the baseline and the 2‐hr samples (p = 0.019). Serum and 
plasma BDNF levels appeared to be inconsistent with each other, 
and the correlations between plasma and serum BDNF levels in each 
measurement varied between 0.187 and 0.636. The variations in 
plasma BDNF levels were large.
The primary aim of this study was to examine the influence 
of ECT on serum and plasma BDNF levels during ECT series and 
whether the levels or change there would act as a predictive factor 
for remission. The study was targeted to examine these processes 
during the single ECT session and throughout the ECT series. To ac‐
complish these aims, the measurement points were defined before 
ECT (baseline) and 2 and 4 hr after ECT at the first, fifth, and last 
session. Since the methodology of the previous studies concerning 
the effects of ECT on BDNF levels has been varying, both serum and 
plasma samples were analyzed in purpose of examining the consis‐
tency between serum and plasma findings.
The	serum	BNDF	levels	 in	the	present	patients	remained	quite	
constant but were remarkably higher than plasma BDNF. Five earlier 
studies have likewise reported no significant effect of ECT on serum 
BDNF levels (Fernandes et al., 2009; Gedge et al., 2012; Grønli et al., 
2009;	Kleimann	et	al.,	2014;	Rapinesi	et	al.,	2015),	but	several	others	
have reported an increase (Bilgen et al., 2014; Bocchio‐Chiavetto et 
al., 2006; Haghighi, Salehi, et al., 2013; Hu et al., 2010; Okamoto 
et al., 2008; Piccinni et al., 2009; Salehi et al., 2016). A recent re‐
view and meta‐analysis found an overall increase in blood BDNF 
levels	after	ECT	series	(Brunoni,	Baeken,	Machado‐Vieira,	Gattaz,	&	
Vanderhasselt,	2014).	A	major	difference	between	these	studies	and	
the present study is the difference in the timing of blood sampling. 
Increase in serum or plasma BDNF levels was measured during the 
treatment period (Bilgen et al., 2014; Marano et al., 2007); in other 
studies, timing of the sampling varied from 1 day after the ECT series 
(Bilgen et al., 2014; Hu et al., 2010) to 1 month after the last ECT 
session (Bilgen et al., 2014; Bocchio‐Chiavetto et al., 2006; Bumb et 
al., 2014; Haghighi, Salehi, et al., 2013; Hu et al., 2010; Marano et al., 
2007; Okamoto et al., 2008; Piccinni et al., 2009; Salehi et al., 2016).
Decreased serum BDNF levels have also been reported after 
ECT session (Stelzhammer et al., 2013). In the present study, the 
blood samples were taken during the whole ECT series; at baseline, 
2, and 4 hr after ECT at the first, fifth, and last ECT session. Thus, 
the different timing of these studies makes them difficult to com‐
pare with the present one. The study by Grønli et al. (2007) resem‐
bles the present one most closely. In that study, serum BDNF levels 
were	measured	during	the	ECT	series	at	baseline	and	five,	15,	30,	
and 60 min after the first, fourth, and eighth ECT session. No change 
was found in serum BDNF levels (Grønli et al., 2009). In the present 
study, the association between remission after ECT and both serum 
and plasma BDNF levels was analyzed. No associations were found 
between any plasma BDNF levels and remission.
Reports of associations between the changes in serum BDNF 
and outcome of ECT have on the whole been contradictory (Pinna et 
al., 2016). Hu et al. (2010) reported significant association between 
the elevation of serum BDNF level and a decreasing rate of MDD 
symptoms (Hu et al., 2010). Okamoto et al. (2008) reported a rise in 
serum BDNF level in responders, whereas, in nonresponders’ serum, 
BDNF levels remained unchanged (Okamoto et al., 2008). On the 
contrary, many other researchers found no correlation between 
serum BDNF levels and alleviation of depressive symptoms (Bilgen 
et al., 2014; Bocchio‐Chiavetto et al., 2006; Bumb et al., 2014; Salehi 
et al., 2016). Accordingly, in one study, ECT and aerobic exercise 
training (BDNF also existing in the muscle tissue) were more effec‐
tive in reducing depressive symptoms than either ECT or aerobic 
exercise training alone. Also, this study found no association be‐
tween	the	plasma	BDNF	levels	and	depression	(Archer,	Josefsson,	&	
Lindwall, 2014; Salehi et al., 2016). These negative findings are con‐
sistent with the outcome of review and meta‐analysis by Brunoni et 
al. (2014) (Brunoni et al., 2014). In the present study, neither serum 
nor plasma BDNF levels predicted the later remission rate after the 
ECT, whereas, in some previous studies, a higher baseline level of 
serum BDNF was associated with treatment response of antidepres‐
sant medication (Mikoteit et al., 2014, 2016). Different mechanisms 
of the therapeutic action between ECT and antidepressant medi‐
cations may explain the differences in the changes in BDNF levels 
between these treatment modalities. The effect of ECT mainly con‐
cerns other signaling systems than serotonin thus exerting less influ‐
ence on BDNF levels (Huuhka et al., 2007, 2008).
F I G U R E  1   Serum BDNF levels in the first, fifth, and last ECT 
sessions
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A fall in the plasma BDNF levels of the present patients was ob‐
served during the fifth ECT session between the baseline and the 2‐
hr samples. Otherwise, no influence of ECT on plasma BDNF levels 
was found. Earlier studies have reported no such decrease in plasma 
BDNF during or after ECT (Haghighi, Salehi, et al., 2013; Lin et al., 
2013; Marano et al., 2007; Piccinni et al., 2009). Instead, some of 
these studies (except (Lin et al., 2013) reported increase in plasma 
BDNF in some point of treatment.
Several studies have reported the effects of various external fac‐
tors on serum and plasma BDNF levels suggesting that BDNF is sensi‐
tive to external factors causing high inter‐ and intraindividual variations 
(Bus et al.., 2011; Chan, Tong, & Yip, 2008; Cubeddu et al., 2011).
Several studies have been published concerning BDNF levels and 
ECT. Four studies measured plasma BDNF levels (Haghighi, Salehi, et 
al., 2013; Lin et al., 2013; Marano et al., 2007; Piccinni et al., 2009), 
and twelve measured serum (Bilgen et al., 2014; Bocchio‐Chiavetto 
et al., 2006; Bumb et al., 2014; Fernandes et al., 2009; Gedge et 
al., 2012; Grønli et al., 2009; Hu et al., 2010; Kleimann et al., 2014; 
Okamoto	 et	 al.,	 2008;	 Rapinesi	 et	 al.,	 2015;	 Salehi	 et	 al.,	 2016;	
Stelzhammer et al., 2013). Both significant change and no change 
in BDNF levels after ECT have been reported with either method. 
The results appeared not to be related to whether plasma or serum 
was used. Furthermore, the findings from serum and plasma studies 
have often been discussed together despite the different methods. 
When comparing the serum and plasma BDNF levels of the present 
study, the correlations were random (0.187–0.636, Pearson correla‐
tion coefficient). Thus, serum and plasma levels of BDNF might not 
be comparable. When assessing the findings of the clinical studies 
regarding	MDD	and	ECT	in	a	meta‐analysis,	Polyakova	et	al.	 (2015)	
reported an increase in plasma BDNF levels but not in serum. Neither 
plasma nor serum BDNF levels did associate with the response of 
ECT	(Polyakova	et	al.,	2015).
Elfving, Plougmann, and Wegener (2010) recommended that 
BDNF should be measured in serum since plasma may be influenced 
by the preanalytical processing of the blood sample. A meta‐analy‐
sis of BDNF in MDD reported greater standard deviations in plasma 
BDNF levels compared to serum BDNF which was also the case in 
the present study. Nevertheless, the number of studies evaluating 
plasma BDNF and MDD was small; thus, no recommendations could 
be made regarding the optimal method for measuring BDNF in blood 
(Brunoni, Lopes, & Fregni, 2008).
Brain‐derived neurotrophic factor is mainly stored in human plate‐
lets, from which it is released through platelet activation and degranu‐
lation of platelets during the clotting process. Therefore, serum BDNF 
levels have been reported to be remarkably higher (approximately 
10–27 ng/ml) than those in plasma (Fujimura et al., 2002; Karege et al., 
2005;	Yamamoto	&	Gurney,	1990).	The	plasma	levels	in	the	present	
study were likewise considerably lower than the serum levels.
The strengths of the study include standardized timing of 
blood sampling during the individual ECT session and through‐
out the ECT series. One prior study has also measured the BDNF 
levels with the resembling methodology (Grønli et al., 2009). The 
present study is a preliminary research since as far as we know no 
other study has compared serum and plasma BDNF levels during 
ECT series.
A limitation of the study is the relatively small number of 
patients. Post hoc power analysis showed that a sample of alto‐
gether	128	patients	would	have	been	required	to	detect	a	differ‐
ence	of	0.5	or	greater	(≥4	ng/ml)	in	effect	size	between	remitters	
and nonremitters with a power of 0.8. Therefore, the small sample 
size may explain the mainly negative findings. Another limitation is 
the assumption that serum or plasma BDNF levels would directly 
reflect	BDNF	 levels	 in	 the	brain.	Kyeremanteng,	 James,	Mackay,	
and Merali (2012) reported no clear correlation between brain and 
serum BDNF after ECS (Kyeremanteng et al., 2012). BDNF expres‐
sion in different brain areas as well as between CSF and serum has 
been reported to have temporal variation following ECS (Angelucci 
et al., 2002; Kyeremanteng et al., 2012, 2014). Peripheral BDNF 
appears to go through specific differential regulation after ECT 
(Bilgen et al., 2014; Bocchio‐Chiavetto et al., 2006; Bumb et al., 
2014; Haghighi, Salehi, et al., 2013; Hu et al., 2010; Okamoto et 
al., 2008; Piccinni et al., 2009; Salehi et al., 2016; Stelzhammer 
et al., 2013). A time delay between brain tissue and serum BDNF 
levels has been reported in both human and rodent studies (Bumb 
et al., 2014; Sartorius et al., 2009). Also, since the patients were 
given psychotropic medication during the study and lacking a con‐
trol group, excluding the plausible effect of medication on serum 
and plasma BDNF levels is unfeasible. However, the possible ef‐
fect of psychotropic medications assumedly remained stable since 
they were kept unchanged throughout the study.
In conclusion, the main finding of this study was that either serum 
or plasma BDNF levels were not associated with remission after ECT 
series in MDD. However, the plasma BDNF levels decreased after 
the fifth ECT session. Thus, predictive value of BDNF for effects 
of ECT remains uncertain. Also, the serum and plasma BDNF levels 
did not appear to be consistent with each other suggesting thus the 
separate methods are not comparable.
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